Pseudomonas vaccine - Aventis Behring

Drug Profile

Pseudomonas vaccine - Aventis Behring

Latest Information Update: 09 Oct 1998

Price : $50

At a glance

  • Originator Aventis Behring LLC
  • Class Bacterial vaccines; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pseudomonal infections

Most Recent Events

  • 09 Oct 1998 No-Development-Reported for Pseudomonal infections in Germany (IM)
  • 19 Nov 1996 Phase-I clinical trials for Pseudomonal infections in Germany (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top